The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Myasthenia gravis: an update for the clinician
Open accessAbstract
Summary: This paper provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Nowadays the term ‘myasthenia gravis’ includes heterogeneous autoimmune diseases, with a postsynaptic defect of neuromuscular transmission as the common feature. Myasthenia gravis should be classified according to the antibody specificity [acetylcholine, muscle-specific receptor tyrosine kinase (MuSK), low-density lipoprotein receptor-related protein 4 (LRP4), seronegative], thymus histology (thymitis, thymoma, atrophy), age at onset (in children; aged less than or more than 50 years) and type of course (ocular or generalized). With optimal treatment, the prognosis is good in terms of daily functions, quality of life and survival. Symptomatic treatment with acetylcholine esterase inhibition is usually combined with immunosuppression. Azathioprine still remains the first choice for long-term immunosuppressive therapy. Alternative immunosuppressive options to azathioprine include cyclosporin, cyclophosphamide, methotrexate, mycophenolate mofetil and tacrolimus. Rituximab is a promising new drug for severe generalized MG. Emerging therapy options include belimumab, eculizumab and the granulocyte– macrophage colony-stimulating factor. One pilot study on etanercept has given disappointing results. For decades, thymectomy has been performed in younger adults to improve non-paraneoplastic MG. However, controlled prospective studies on the suspected benefit of this surgical procedure are still lacking. In acute exacerbations, including myasthenic crisis, intravenous immunoglobulin, plasmapheresis and immunoadsorption are similarly effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001) · Nature Medicine · doi:10.1038/85520 · Cited by 1,183
IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†
Leite, M. I., Jacob, S., Viegas, S., Cossins, J., Clover, L., Morgan, B. P., Beeson, D., Willcox, N., & Vincent, A. (2008) · Brain · doi:10.1093/brain/awn092 · Cited by 527
To build a synapse: signaling pathways in neuromuscular junction assembly
Wu, H., Xiong, W. C., & Mei, L. (2010) · Development · doi:10.1242/dev.038711 · Cited by 519
A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis
Palace, J., Newsom-Davis, J., Lecky, B., & Myasthenia Gravis Study Group (1998) · Neurology · doi:10.1212/wnl.50.6.1778 · Cited by 473
Long-lasting treatment effect of rituximab in MuSK myasthenia
Díaz-Manera, J., Martínez-Hernández, E., Querol, L., Klooster, R., Rojas-García, R., Suárez-Calvet, X., Muñoz-Blanco, J. L., Mazia, C., Straasheijm, K. R., Gallardo, E., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182407982 · Cited by 346
Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis
Pevzner, A., Schoser, B., Peters, K., Cosma, N.-C., Karakatsani, A., Schalke, B., Melms, A., & Kröger, S. (2012) · Journal of Neurology · doi:10.1007/s00415-011-6194-7 · Cited by 342
Tzartos, J. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2393 · Cited by 342
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
Sanders, D. B., Hart, I. K., Mantegazza, R., Shukla, S. S., Siddiqi, Z. A., De Baets, M. H. V., Melms, A., Nicolle, M. W., Solomons, N., & Richman, D. P. (2008) · Neurology · doi:10.1212/01.wnl.0000312374.95186.cc · Cited by 318
Howard, J. F., Barohn, R. J., Cutter, G. R., Freimer, M., Juel, V. C., Mozaffar, T., Mellion, M. L., Benatar, M. G., Farrugia, M. E., Wang, J. J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23839 · Cited by 225
A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis
The Muscle Study Group (2008) · Neurology · doi:10.1212/01.wnl.0000312373.67493.7f · Cited by 225
Cited by
Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0079-y · Cited by 953
Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103483 · Cited by 326
rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
Ishii, A., Okada, H., Hayashita-Kinoh, H., Shin, J.-H., Tamaoka, A., Okada, T., & Takeda, S. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.012 · Cited by 18
Metadata
- Authors
- Sieb, J. P.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-04
- Volume
- 175
- Issue
- 3
- Pages
- 408-418
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W1645572349
- Cited by
- 283
- References
- 36
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myasthenia gravis: an update for the clinician. https://app.cochat.ai/papers/10.1111/cei.12217
- The paper
- Sieb, J. P. (2014). Myasthenia gravis: an update for the clinician. Clinical and Experimental Immunology. https://doi.org/10.1111/cei.12217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.